Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.72. The company's market cap stands at 146.33B, with a P/E ratio of 19.64 and a dividend yield of 6.7%.
On 2026-06-09, Pfizer(PFE) stock moved within a range of $25.47 to $25.88. With shares now at $25.72, the stock is trading +1.0% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 35.27M, compared to an average daily volume of 34.54M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.
PFE News
RBC Capital upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target Published first on TheFly – the ultimate source for real-time, ma...
Earn $5,000+ Yearly With These 4 Dividend Stocks By Vandita Jadeja Published Jun 9, 2:53PM EDT Quick Read Pfizer yields 6.70% and Verizon 6.23%, making them t...
Goldman Sachs analyst Asad Haider has maintained their neutral stance on PFE stock, giving a Hold rating on June 7. Asad Haider has given his Hold rating due t...
Analyst ratings
59%
of 29 ratingsMore PFE News
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer-Backed Bladder Cancer Study Pits Novel Combo Against Standard Care This Phase 3 t...
Pfizer (PFE) announced that the U.S. FDA has approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years a...
Pfizer (PFE) presented detailed results from multiple Phase 2b studies of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agon...
Key Points Pfizer’s net income is under pressure, and likely will be for the foreseeable future. Although its replenished pipeline and portfolio should help,...
Key Points Pfizer is a highly respected pharmaceutical company. The drug maker is dealing with a mismatch between its new drug development and patent expirati...
Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 55% Off TipRanks Unlock trusted, data-backed i...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.